Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658615 | 0.77 | P4HTM (0.50) | P4HTMMEN1KMT2AKDM4CCREBBP | |
| SCHEMBL5376202 | 0.75 | P4HTM (0.48) | P4HTMMEN1KMT2AKDM4CCREBBP | |
| SCHEMBL5557293 | 0.74 | HDAC6 (0.45) | MEN1KMT2AKDM4EHDAC1HDAC8 | |
| SCHEMBL5557284 | 0.74 | HDAC6 (0.45) | MEN1KMT2AKDM4EHDAC1HDAC8 | |
| SCHEMBL5375510 | 0.73 | HRH3 (0.50) | P4HTMMEN1KMT2AKDM4CMAOB | |
| SCHEMBL5379438 | 0.73 | LMNA (0.48) | P4HTMMEN1KMT2AKDM4CHDAC6 | |
| SCHEMBL6132863 | 0.72 | OPRK1 (0.44) | KDM4EHDAC6ALDH1A1OPRK1 | |
| SCHEMBL5392310 | 0.72 | MMP1 (0.47) | P4HTMMEN1KMT2AKDM4CMAOB | |
| SCHEMBL4722336 | 0.71 | MEN1 (0.48) | P4HTMMEN1KMT2AMAOBGRM5 | |
| SCHEMBL4722331 | 0.71 | MEN1 (0.48) | P4HTMMEN1KMT2AMAOBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282609-B1 | PIPERAZINEDIONE COMPOUNDS | ANGIORX CORP (TW) | 2008-12-17 | — | — | EP | disclosed |
| US-7288545-B2 | Piperazinedione compounds | ANGIORX CORPORATION (TW) | 2007-10-30 | — | — | US | disclosed |
| US-20040132738-A1 | Piperazinedione compounds | ANGIORX CORPORATION (TW) | 2004-07-08 | — | — | US | disclosed |
| US-6635649-B2 | 3-((5-butoxy-pyrid-2-yl)methylene),6-benzylidene-piperazin-2,5 -dione, for example; treating tumors | ANGIORX CORPORATION (TW) | 2003-10-21 | — | — | US | disclosed |
| EP-1282609-A4 | PIPERAZINEDIONE COMPOUNDS | ADPHARMA INC (TW) | 2003-06-04 | — | — | EP | disclosed |
| EP-1282609-A2 | PIPERAZINEDIONE COMPOUNDS | Adpharma Inc. (TW) | 2003-02-12 | — | — | EP | disclosed |
| US-20020028819-A1 | Piperazinedione compounds | ANGIORX CORPORATION (TW) | 2002-03-07 | — | — | US | disclosed |
| WO-2001095858-A2 | PIPERAZINEDIONE COMPOUNDS | ADPHARMA, INC. (TW) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028819-A1 | Piperazinedione compounds | DRD1, DRD3, DRD2 | P4HTM 2859/4885MEN1 4286/4885KMT2A 1994/4885 |
| US-20040132738-A1 | Piperazinedione compounds | CBR1, KDR, FLT1 | P4HTM 1191/4885MEN1 4806/4885KMT2A 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.